menu
    • menu

    Company profile for Opna Bio

    NEW Drugs in Dev: 3
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Opna Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics. The company’s broad portfolio targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-X mental retardation protein (FMRP) and a diversified pipeline of validated oncology assets acquired from Plexxikon. The Opna team has a proven track record of scient...
    Opna Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics. The company’s broad portfolio targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-X mental retardation protein (FMRP) and a diversified pipeline of validated oncology assets acquired from Plexxikon. The Opna team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market. In addition to its discovery-stage FMRP program.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Opna BioSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Route de la Corniche 6 1066 Epalinges
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.opnabio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Opna Bio Receives Orphan Drug Designation For OPN-2853
    Opna Bio Receives Orphan Drug Designation For OPN-2853

    21 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260121834497/en/Opna-Bio-Announces-Orphan-Drug-Designation-Granted-to-OPN-2853-Zavabresib-for-the-Treatment-of-Myelofibrosis

    BUSINESSWIRE
    21 Jan 2026
    Share Share
    Opna Bio Highlights Dual-Action Therapy For Myeloma
    Opna Bio Highlights Dual-Action Therapy For Myeloma

    08 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251208736143/en/Opna-Bio-Showcases-Multi-Functional-Degraders-with-Potent-Anti-Myeloma-Activity-and-Encouraging-Spleen-Reductions-in-Patients-with-Myelofibrosis-Treated-with-OPN-2853-and-Ruxolitinib

    BUSINESSWIRE
    08 Dec 2025
    Share Share
    Opna Bio Announces 2025 ASH Presentations on Preclinical Data
    Opna Bio Announces 2025 ASH Presentations on Preclinical Data

    04 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251104080483/en/Opna-Bio-Announces-2025-ASH-Presentations-Highlighting-Preclinical-Data-from-Novel-Protein-Degrader-Program-and-Updated-Interim-Data-from-Phase-1-Combination-Study-of-OPN-2853-with-Ruxolitinib-in-Advanced-Myelofibrosis

    BUSINESSWIRE
    04 Nov 2025
    Share Share
    Opna Bio Gets Orphan Drug Status For OPN-6602 In Multiple Myeloma
    Opna Bio Gets Orphan Drug Status For OPN-6602 In Multiple Myeloma

    12 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250212175926/en

    BUSINESSWIRE
    12 Feb 2025
    Share Share
    Opna Bio Announces Phase 1 Data for OPN-2853 in Myelofibrosis
    Opna Bio Announces Phase 1 Data for OPN-2853 in Myelofibrosis

    09 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241209262691/en

    BUSINESSWIRE
    09 Dec 2024
    Share Share
    Opna Bio to Present Data at ASH on BET Inhibitor in Myelofibrosis
    Opna Bio to Present Data at ASH on BET Inhibitor in Myelofibrosis

    13 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241113176172/en

    BUSINESSWIRE
    13 Nov 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search